Detalles de la búsqueda
1.
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
Oncologist
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38815152
2.
Psychometric evaluation of the respiratory syncytial virus infection, intensity and impact questionnaire (RSV-iiiQ) in adults.
Health Qual Life Outcomes
; 22(1): 19, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38378572
3.
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Clin Infect Dis
; 77(11): 1521-1530, 2023 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466374
4.
Assessing the patient experience of respiratory syncytial virus infection: development of a patient-reported outcome measure.
Health Qual Life Outcomes
; 21(1): 20, 2023 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36855175
5.
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(5): 665-677, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33812497
6.
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
Cancer
; 127(6): 865-874, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33231873
7.
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer
; 24(6): 1330-1340, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363528
8.
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.
JAMA
; 319(5): 483-494, 2018 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29411037
9.
Psychometric validation of the dysmenorrhea daily diary (DysDD): a patient-reported outcome for dysmenorrhea.
Qual Life Res
; 26(8): 2041-2055, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28405780
10.
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer
; 24(6): 1341, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34536168
11.
International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies.
Qual Life Res
; 25(2): 359-362, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26275979
12.
A qualitative study to develop a patient-reported outcome for dysmenorrhea.
Qual Life Res
; 24(1): 181-91, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25048731
13.
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey.
Patient
; 17(2): 147-159, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38085458
14.
Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration.
Qual Life Res
; 21(6): 1013-20, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21909804
15.
Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Measurement Properties and Estimated Clinically Meaningful Thresholds From a Phase 3 Study.
JTO Clin Res Rep
; 3(4): 100298, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35400081
16.
Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
Eur J Heart Fail
; 24(5): 843-850, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274420
17.
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
J Clin Oncol
; 40(4): 382-391, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34730989
18.
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
Eur J Cancer
; 169: 188-197, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35588692
19.
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Oral Oncol
; 128: 105815, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35381576
20.
Development and validation of the Influenza Intensity and Impact Questionnaire (FluiiQ™).
Value Health
; 14(5): 687-99, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21839407